Entresto Risk Sharing Could Equate To 8.6% Discount, ICER Says; Is Express Scripts Interested?
This article was originally published in The Pink Sheet Daily
Executive Summary
Cost effectiveness report on Novartis’ new heart failure drug includes a hypothetical risk-sharing payment model using hospitalization or death as patient endpoints; Express Scripts exec notes outcomes-based contracts have been problematic but hints at potential for Entresto.
You may also be interested in...
Novartis' Entresto: Slow Uptake Expected Following Fast FDA Approval
Reimbursement complexity and physician reluctance to move stable patients off their current treatment regimens are the biggest hurdles.
FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says
The agency is also poised to announce another development in its scrutiny of the drug patents listed in the FDA’s Orange Book.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.